Evidence map›Paper›PMID 33911910›Full record

ArticleClinical Medicine Insights. Cardiology2021

Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.

Alessandro Lupi, Sara Ariotti, Doranna De Pace, Irene Ferrari, Stefano Bertuol, Lorenzo Monti, Luigina Guasti, Giovanni Vincenzo Gaudio, Carlo Campana

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alessandro LupiDepartment of Cardiology, ASL14 Verbano-Cusio-Ossola, Ospedale Castelli, Verbania, Italy.ORCID https://orcid.org/0000-0003-3644-0449
Sara AriottiDepartment of Cardiology, ASL14 Verbano-Cusio-Ossola, Ospedale Castelli, Verbania, Italy.
Doranna De PaceDepartment of Cardiology, ASL14 Verbano-Cusio-Ossola, Ospedale Castelli, Verbania, Italy.
Irene FerrariDepartment of Cardiology, ASL14 Verbano-Cusio-Ossola, Ospedale Castelli, Verbania, Italy.
Stefano BertuolDepartment of Cardiology, ASL14 Verbano-Cusio-Ossola, Ospedale Castelli, Verbania, Italy.
Lorenzo MontiRadiology and Cardiology Department, Humanitas Research Hospital, Rozzano (MI), Italy.
Luigina GuastiResearch Center on Dyslipidemia, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Giovanni Vincenzo GaudioDepartment of Medicine, Somma Lombardo Hospital, Varese, Italy.
Carlo CampanaCardiology Department, Sant'Anna Hospital, Como, Italy.
IRCCS Humanitas Research Hospital · ITUniversity of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Experience with angiotensin-receptor neprilysin inhibitors (ARNI) in oncologic patients with heart failure (HF) is limited. We report a case of ARNI started as first-choice therapy in a patient with relapsing hairy cell leukaemia (HCL) and HF with depressed left ventricular ejection fraction (LVEF). A middle-aged male, previously treated with rituximab for HCL, was scheduled for cardiologic screening before starting a new antineoplastic therapy for cancer relapse. The patient had symptomatic HF with reduced LVEF and high NT-proBNP levels. In this patient, early ARNI treatment was well tolerated and produced a rapid and durable improvement of symptoms, LVEF and NT-proBNP levels. Consequently, the oncologic team could start an experimental treatment with obinutuzumab, with complete HCL remission. In conclusion, in this patient with HCL and HF, ARNI therapy was safe and effective, contributing to undelayed cancer treatment.

Indexed as

ARNIchemotherapyhairy cell leukaemiaheart failureSacubitril/valsartan

Identifiers

PMID33911910
PMCPMC8050758
OpenAlexW3156345952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.